Dr. Lal Path Labs Ltd. has informed the Exchange regarding 'Submission of Business Responsibility and Sustainability Report for the Financial Year 2024-25'.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 to NSE and BSE, as required under SEBI's Listing Regulations. The report is on a standalone basis but also includes data from Suburban Diagnostics, whose business was transferred to the company on a going-concern basis following its voluntary liquidation effective March 18, 2025. The company operates 298 labs across 27 states and 5 union territories in India, plus labs in Nepal and Bangladesh, with FY25 turnover of ₹2,351.6 crore and net worth of ₹2,077.1 crore. It employs 1,830 permanent and other-than-permanent employees and 3,478 workers, with women forming about 26–28% of the workforce. The company holds NABL accreditation for 40 labs, CAP accreditation for 2 reference labs, and ISO 27001 certification, and spent ₹94.53 million on CSR activities including healthcare programs and phlebotomist training in rural areas.
This is a routine annual ESG compliance filing with no new financial or strategic announcement, so it is unlikely to move the stock price. Shareholders gain additional transparency on the company's sustainability, employee welfare, and governance practices, and the Suburban Diagnostics consolidation has now been formally absorbed into the reporting boundary.